Physician profile
Donald Kay
NPI 1740287960
$3,501.38
in general payments reported to CMS, 2019-2025
14 companies · $32.00 in 2025
The $32.00 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $454 · 2021: $1,005 · 2022: $236 · 2023: $645 · 2024: $376 · 2025: $32.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,053.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,480.13 | 2019-2023 | |
| Abbvie INC. | $1,049.34 | 2019-2025 | |
| Pfizer INC. | $171.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $140.57 | 2019-2020 | |
| Lilly USA, LLC | $137.43 | 2019-2020 | |
| Janssen Biotech, INC. | $137.14 | 2019-2020 | |
| Genzyme Corporation | $87.98 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $71.55 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $55.93 | 2019-2020 | |
| Leo Pharma INC. | $53.15 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.32 | 2019-2020 | |
| Amgen INC. | $27.85 | 2019 | |
| Biofrontera INC. | $22.49 | 2019 | |
| Aclaris Therapeutics, INC. | $20.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.